Free Republic

A new COVID-19 vaccine has achieved 100 percent efficacy against severe disease and hospitalizations, announced manufacturers Sanofi and GSK on Wednesday. The companies are now set to apply for regulatory authorization from bodies like the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) to release the vaccine as both a two-dose vaccine and booster shot. Unlike vaccines based on mRNA technology, the new Sanofi-GSK offering is a protein-based vaccine – a “well-established approach that has been applied widely to prevent infection with other viruses including pandemic flu,” said GSK President Roger Connor in a statement today. “We...

A new vaccine manufactured in Europe by Sanofi and GSK claims 100% efficacy against severe disease and hospitalizations, and it could be an effective booster after other COVID-19 shots, according to the manufacturers. The companies received billions of dollars from Donald Trump’s brainchild, “Operation Warp Speed.” Since Biden isn’t calling it that anymore, how are they going to describe where the money came from? The two-shot Sanofi-GSK vaccine is expected to be approved by the FDA for emergency use in next few weeks.New York Times:In laboratory studies, two doses of the Sanofi-GSK vaccine stimulated the production of more neutralizing antibodies...

The CDC is horribly compromised, according to its own description of how it functions with private funds collected by the CDC Foundation.CDC is a Private Organization - Not Government! [Donors include Bill and Melinda Gates Foundation, three separate PFizer foundations, Merck, Bloomberg, George Soros' Open Society Foundation, Rothschild, Rockefeller, Sanofi, Merck etc.]Post #1 of that thread lists the long list of donors to the CDC Foundation.It claims it's restrained from violations of integrity by charter. With utterly lawless, remorseless actions, the CDC steadily erodes and violates our Constitutional Rights and we're to believe they're going to daintily adhere to a...

Big Pharma did not like Donald Trump, but they certainly like Joe Biden – especially now. In an ongoing frenzy to undo everything Trump did over the last four years, Joe Biden froze a December rule aimed at lowering prescription drug prices for insulin and epinephrine. On Thursday, Biden’s Department of Health and Human Services announced the new rule would be put on hold, along with several other Trump-era orders pending a 60 day review, The Federalist reports. Biden Chief of Staff Ron Klain directed federal agencies on Wednesday to pause orders that had been signed and published by Trump’s...

This video starts out with a few short clips and then around the 3 minute 30 second mark, the internal medicine physician (shown above) begins talking about the medical issues specific to the vaccine that Bill Gates has rushed through. [I don't know the spelling of her last name but you can hear her pronounce it in the video]Note: It's a little distracting that part of the first brief clip is repeated once - but it's a good clip and very short in duration (worth repeating). The man speaking during the introductory clips is attorney Robert Kennedy Jr., who has scandalized...

French drugmaker Sanofi SA said on Tuesday it expects to get approval for the potential COVID-19 vaccine it is developing with Britain’s GlaxoSmithKline Plc by the first half of next year, faster than previously anticipated. Sanofi, which is hosting a virtual research and development event, and GSK had said in April the vaccine, if successful, would be available in the second half of 2021. “We are being guided by our dialogue with regulatory authorities,” Sanofi research chief John Reed told reporters, when asked about the accelerated time frame. There are currently no vaccines to prevent the coronavirus that has infected...

French pharmaceutical group Sanofi promised Thursday that it would make its COVID-19 vaccine, when ready, available in all countries, hours after the company’s CEO said the United States will get first access. Sanofi CEO Paul Hudson’s comments that a vaccine would go first to the U.S. prompted an angry reaction from the French government. “Equal access for all to the vaccine is not negotiable,” French Prime Minister Edouard Philippe said in a tweet. French President Emmanuel Macron was described by his office as also being “upset” by Hudson’s comments. Macron is pushing for vaccines to be considered a “common good”...

The HuffPost on Tuesday published a story claiming President Trump owned a share in a company that manufactured hydroxychloroquine, the anti-malaria drug the president and others have touted as a possible treatment for coronavirus. The story, titled “Donald Trump Has Stake In Hydroxychloroquine Drugmaker: Report,” argues that Trump “reportedly owns a stake in a company that produces hydroxychloroquine, the anti-malaria drug he has repeatedly touted as a coronavirus treatment even though his experts say there’s no strong evidence it works.” The story goes on to cite a New York Times story that Trump “has a small personal financial interest” in...

President Donald Trump reportedly owns a stake in a company that produces hydroxychloroquine, the anti-malaria drug he has repeatedly touted as a coronavirus treatment even though his experts say there’s no strong evidence it works. Trump “has a small personal financial interest” in Sanofi, the French drugmaker that makes Plaquenil, the brand-name version of hydroxychloroquine, The New York Times reported Monday. In addition, Sanofi’s largest shareholders include a mutual fund company run by major Republican donor Ken Fisher, the paper said. Trump’s three family trusts, as of last year, each had investments in a mutual fund whose largest holding was...

PARIS, April 2 (Reuters) - Sanofi SA will be able to provide millions of doses of hydroxychloroquine for patients with the illness caused by the novel coronavirus if the old malaria drug proves successful in clinical trials, its chief executive told Reuters on Thursday. Paul Hudson, who became CEO of the French drugmaker in September, said in an interview that the company is currently manufacturing at over 93% capacity during the pandemic. He said the company had made a choice to "overproduce" its drugs to ensure supplies for hospitals in Europe and the United States facing an unprecedented crush of...

French pharmaceutical giant Sanofi on Friday said the European Medicines Agency had conditionally approved its anti-cancer drug Libtayo, the first drug of its kind to be authorized for use in the EU. The tumor-reducing drug is aimed at patients with the second most common form of skin cancer — cutaneous squamous cell carcinoma (CSCC) — whose cancer is advanced, and who are not candidates for surgery or radiation therapy. […] The US Food and Drug Administration (FDA) approved Libtayo in September 2018, while Health Canada gave it the conditional green light earlier this month. …

Donald J. Trump told the American people during his presidential campaign, “This country is being drained of its jobs and its money because we have stupid people making bad deals.” He promised to make better deals, ones in which we would win so much we “may even get tired of winning.” Now his administration, through the Army, is on the brink of making a bad deal, giving a French pharmaceutical company, Sanofi, the exclusive license to patents and thus a monopoly to sell a vaccine against the Zika virus. If Mr. Trump allows this deal, Sanofi will be able to...

Sanofi US Issues Voluntary Nationwide Recall of Auvi‑Q® Due to Potential Inaccurate Dosage Delivery Sanofi US is voluntarily recalling all Auvi‑Q® (epinephrine injection, USP). The recall involves all Auvi‑Q currently on the market and includes both the 0.15 mg and 0.3 mg strengths for hospitals, retailers and consumers. This includes lot number 2299596 through 3037230, which expire March 2016 through December 2016. The products have been found to potentially have inaccurate dosage delivery. If a patient experiencing a serious allergic reaction (i.e., anaphylaxis) did not receive the intended dose, there could be significant health consequences, including death because anaphylaxis...

Hoping to appeal to millions of needle-phobic Americans with diabetes, drugmakers Sanofi and Mannkind have just launched Afrezza, an insulin that's inhaled, rather than injected. Afrezza was approved by the Food and Drug Administration last June for patients with either Type 1 or 2 diabetes, to be used along with other medicines, diet and exercise. Paris-based Sanofi SA, a major player in the huge diabetes treatment market, then licensed Afrezza's worldwide marketing rights from Mannkind Corp. of Valencia, California, which developed Afrezza.

Chinese authorities have launched an investigation against French drugmaker Sanofi following a news report that accused the company of bribing hundreds of Chinese doctors in 2007. An unnamed whistleblower told the Guangzhou-based, state-owned 21st Century Business Herald that the French company had paid 503 doctors a total of $274,000 to prescribe Sanofi products, disguising the payments as grants for research programs. China’s official Xinhua News Agency said Saturday that the Beijing municipal health bureau was teaming up with disciplinary authorities to look into the research programs and determine whether the payments were actually bribes. …

Chattanooga-based Chattem has carried out the biggest product launch in its 130-year history and one of the largest ever in the city. “It’s an exciting time for us,” Chattem President Bob Bosworth said about the massive rollout of allergy drug Allegra last week to more than 25,000 stores nationwide. First-day shipments to stores hit about $100 million, according to the company. Bosworth said Allegra, shifting from a prescription drug to an over-the-counter medicine, is targeting the No. 1 slot in its segment by lapping competitors Claritin and Zyrtec. Zan Guerry, Chattem’s chief executive, said the company is aiming for annual...

Armed with a $190 million order from the U.S. Department of Health and Human Services, Sanofi Pasteur could begin production of a swine flu vaccine at one of its two Swiftwater facilities as soon as next month. Announcing the news Monday, Sanofi noted the order was issued under an existing pandemic stockpile contract with the U.S. News comes just two weeks after the U.S. Food and Drug Administration issued a license for Sanofi's new, $150 million, 140,000-square-foot vaccine manufacturing plant at Swiftwater. That's where initial work would begin, while an existing plant at the complex continues work on seasonal flu...